Tango Therapeutics, Inc.
General ticker "TNGX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.2B (TTM average)
Tango Therapeutics, Inc. follows the US Stock Market performance with the rate: 47.6%.
Estimated limits based on current volatility of 3.6%: low 21.71$, high 23.35$
Factors to consider:
- Total employees count: 137 (-11.6%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Difficulty obtaining financing, Regulatory and compliance, Clinical trial delays, Manufacturing capacity, Market competition
- Current price 83.6% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.56$, 12.00$]
- 2026-12-31 to 2027-12-31 estimated range: [3.46$, 9.48$]
Financial Metrics affecting the TNGX estimates:
- Positive: with PPE of -10.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Shareholder equity ratio, % of 86.83 > 81.92
- Negative: Inventory ratio change, % of 29.52 > 4.02
- Negative: Investing cash flow per share per price, % of -4.05 <= -2.60
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0
Short-term TNGX quotes
Long-term TNGX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $36.53MM | $42.07MM | $62.38MM |
| Operating Expenses | $150.70MM | $187.66MM | $173.67MM |
| Operating Income | $-114.17MM | $-145.59MM | $-111.29MM |
| Non-Operating Income | $12.56MM | $15.50MM | $9.70MM |
| R&D Expense | $115.20MM | $143.92MM | $132.16MM |
| Income(Loss) | $-101.61MM | $-130.09MM | $-101.59MM |
| Taxes | $0.13MM | $0.21MM | $0.00MM |
| Net Income(Loss)* | $-101.74MM | $-130.30MM | $-101.59MM |
| Stockholders Equity | $253.11MM | $199.52MM | $346.18MM |
| Assets | $402.57MM | $316.49MM | $398.69MM |
| Operating Cash Flow | $-117.98MM | $-131.50MM | $-138.89MM |
| Capital expenditure | $1.53MM | $0.75MM | $1.05MM |
| Investing Cash Flow | $41.43MM | $86.13MM | $-40.87MM |
| Financing Cash Flow | $82.41MM | $47.66MM | $222.50MM |
| Earnings Per Share** | $-1.08 | $-1.19 | $-0.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.